Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KCNJ6 | P48051 | 5/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 5/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298420 | 0.82 | APLNR (0.37) | ALDH1A1KDM4ETDP1APLNRKCNJ6 | |
| SCHEMBL661658 | 0.81 | GRM5 (0.38) | ALDH1A1HPGDKDM4EALOX15HSD17B10 | |
| SCHEMBL661852 | 0.81 | CTNNB1 (0.34) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL661279 | 0.76 | HPGD (0.37) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL297985 | 0.74 | MAPT (0.35) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL27855104 | 0.73 | APLNR (0.31) | ALDH1A1KDM4EAPLNRKCNJ6KCNJ3 | |
| SCHEMBL286895 | 0.72 | SMN1; SMN2 (0.34) | MAPT | |
| SCHEMBL287276 | 0.71 | ALDH1A1 (0.35) | ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL7808911 | 0.67 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4EMAPTPOLB | |
| SCHEMBL27871720 | 0.66 | MAPT (0.33) | ALDH1A1HPGDKDM4EHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | ALDH1A1 676/4885HPGD 202/4885KDM4E 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.